Title
Diagnostic performance of soluble Mesothelin and Megakaryocyte potentiating factor in Mesothelioma Diagnostic performance of soluble Mesothelin and Megakaryocyte potentiating factor in Mesothelioma
Author
Faculty/Department
Faculty of Medicine and Health Sciences
Publication type
article
Publication
New York ,
Subject
Pharmacology. Therapy
Human medicine
Source (journal)
American journal of respiratory and critical care medicine. - New York, 1994, currens
Volume/pages
181(2010) :6 , p. 620-625
ISSN
1073-449X
1535-4970
1073-449X
ISI
000280446500016
Carrier
E
Target language
English (eng)
Full text (Publishers DOI)
Affiliation
University of Antwerp
Abstract
Rationale: Soluble mesothelin (SM) is currently the reference serum biomarker of malignant pleural mesothelioma (MPM). Megakaryocyte potentiating factor (MPF), which originates from the same precursor protein, is potentially more sensitive, yet lacks validation. Objectives: To analyze the diagnostic performance ofMPFas anMPM biomarker and compare this performance with SM. Methods: A total of 507 participants were enrolled in six cohorts: healthy control subjects (n 5 101), healthy asbestos-exposed individuals (n589), andpatients with benign asbestos-related disease (n5123), benign respiratory disease (n546), lung cancer (n563), and MPM (n 5 85). Sera were analyzed for SM and MPF levels using the Mesomark and Human MPF ELISA kit, respectively. Measurements and Main Results: SM and MPF levels differed significantly between patients withMPMand participants from each other cohort (P , 0.001). Receiver operating characteristics curve analysis did not reveal a significant difference between both markers in area under curve (AUC) for distinguishing MPM from all cohorts jointly (SM 5 0.871, MPF 5 0.849; P 5 0.28). At 95% specificity, SM and MPF had a sensitivity of 64% (cutoff 5 2.00 nmol/L) and 68% (cutoff 5 12.38 ng/ml), respectively. Combining both markers did not improve the diagnostic performance. Conclusions: Inthis prospective multicenter study,MPFis validated as a highly performant MPM biomarker. The similar AUC values of SM and MPF, together with the limited difference in sensitivity, show that both serum biomarkers have an equivalent diagnostic performance
E-info
https://repository.uantwerpen.be/docman/iruaauth/c4bcb2/63e6ecb3260.pdf
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000280446500016&DestLinkType=RelatedRecords&DestApp=ALL_WOS&UsrCustomerID=ef845e08c439e550330acc77c7d2d848
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000280446500016&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=ef845e08c439e550330acc77c7d2d848
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000280446500016&DestLinkType=CitingArticles&DestApp=ALL_WOS&UsrCustomerID=ef845e08c439e550330acc77c7d2d848
Handle